Discovery Life Sciences, a global provider of biospecimen solutions and laboratory services, has opened a new office and laboratory facility at 200 Exchange St. in Malden, Massachusetts.
 
This facility, covering over 53,000 square feet, marks a milestone as Discovery’s seventh facility in the United States and its third in the Greater Boston area, joining existing sites in Woburn and Quincy.
 
The Malden facility is designed to serve the region’s dynamic pharma and biotech industry. It will house Discovery’s Gentest products and services, which focus on in vitro preclinical studies for drug metabolism and predictive toxicology, alongside a clean room and cell processing laboratory to enhance its AllCells offerings, which provide high-quality cell and gene therapy cryo-preserved GMP products on the East Coast.
 
“Our new Malden facility underscores our mission to enable the discovery and development of therapeutic solutions that improve patient outcomes,” said Discovery CEO Greg Herrema. “By expanding our footprint in the Greater Boston area in response to growing customer demand, we enhance our capacity to deliver same-day, cutting-edge cell and gene therapy solutions to biopharma customers based in the New England region.”
 
“Our continued investment in this region demonstrates our dedication to being the most trusted partner in life sciences research and clinical development,” added Marshall Schreeder, president of Discovery’s preclinical division. “The new Malden facility will play a crucial role in supporting the continued growth of our Gentest business, offering enhanced capabilities for drug metabolism studies and predictive toxicology, which are essential for drug discovery and development.”
 
Discovery operates globally, with laboratories and offices in the United States and Europe.